Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133781 · ClinicalTrials.gov registry record · Phase 4
B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
A Phase 4 study of Influenza, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT02133781: Completed Phase 4 study of Influenza, sponsored by Stanford University.
NCT02133781 is a Phase 4 study of Influenza that has completed, run by Stanford University. The registered enrollment target is 51 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02133781, a Phase 4 study of Influenza, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an exploratory study using a strategy that has not been previously employed to investigate the effects of age and vaccine type on specific kinds of immune responses to licensed, seasonal 2009-2010 influenza vaccines in children and adults.
Conditions Studied
Interventions
- BIOLOGICAL Fluzone® 2009-2010 Formula
- BIOLOGICAL FluMist® 2009-2010 Formula
Study Locations (1)
California
- Stanford LPCH Vaccine Program - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
What the finished NCT02133781 record still lists
NCT02133781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Fluzone® 2009-2010 Formula is the first listed.
NCT02133781 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02133781 about?
NCT02133781 is a clinical study titled "B-cell Immunity to Influenza (SLVP017)- Year 1, 2009". This is an exploratory study using a strategy that has not been previously employed to investigate the effects of age and vaccine type on specific kinds of immune responses to licensed, seasonal 2009-2010 influenza vaccines in children and adults.
What is the current status of trial NCT02133781?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2009-07. Estimated completion is 2009-12.
What conditions does trial NCT02133781 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT02133781?
The interventions under investigation include: Fluzone® 2009-2010 Formula (BIOLOGICAL), FluMist® 2009-2010 Formula (BIOLOGICAL).
Who is sponsoring clinical trial NCT02133781?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02133781 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02133781's enrollment target sits among peer trials
51 127th of 156 higher than 29 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Bone Marrow and Peripheral Blood Immune Responses Study
RECRUITING · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
COMPLETED · Phase 4
-
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
COMPLETED · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia